<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9"
        xmlns:news="http://www.google.com/schemas/sitemap-news/0.9"
        xmlns:image="http://www.google.com/schemas/sitemap-image/1.1">
  <url>
    <loc>https://www.pharmanow.live/latest-news/fda-verified-clinical-benefit-non-malignant-neurological-accelerated-approvals-2026</loc>
    <lastmod>2026-11-19T22:54:10+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T00:00:00+05:30</news:publication_date>
      <news:title>FDA Updates Clinical Benefit List for Non-Malignant and Neurological Accelerated Approvals</news:title>
      <news:keywords>FDA</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/630a5211-4774-4167-8685-91b046240fc2/a49ba69f-8eb0-4d34-a95a-ef6a9388da2d.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/abbvie-217-million-barceloneta-puerto-rico-biologics-campus-modernization</loc>
    <lastmod>2026-11-19T22:57:15+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T00:00:00+05:30</news:publication_date>
      <news:title>AbbVie Invests $217 Million to Modernize Barceloneta Biologics Campus</news:title>
      <news:keywords>AbbVie</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/630a5211-4774-4167-8685-91b046240fc2/e6d07652-02bb-45ad-96fe-f3a8108c84c4.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/evotec-bms-second-fda-ind-acceptance-celmod-molecular-glue-degrader</loc>
    <lastmod>2026-11-19T22:52:30+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T00:00:00+05:30</news:publication_date>
      <news:title>Evotec Achieves IND Acceptance for CELMoD Molecular Glue Degrader</news:title>
      <news:keywords>Evotec</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/02fa5714-b6fe-4451-b649-907e1e675581/a4c402db-74c6-4a17-9d49-205029467aaa.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/genzyme-fda-approval-infilbray-gaucher-disease-type-3-neurological</loc>
    <lastmod>2026-11-19T22:49:49+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T00:00:00+05:30</news:publication_date>
      <news:title>Genzyme Gains FDA Approval for Infilbray as First GD3 Neurological Treatment</news:title>
      <news:keywords>Genzyme</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/4aec1a28-5bd8-4a07-b136-84165ef9c4af/37950e99-899d-477b-a2e7-1a7e2bafc343.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/ektah-advances-nks3-obesity-drug-phase-iia-24-million-funding</loc>
    <lastmod>2026-11-19T12:01:47+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T00:00:00+05:30</news:publication_date>
      <news:title>EktaH Advances NKS-3 Obesity Drug into Phase IIa</news:title>
      <news:keywords>EktaH</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/ektah-nks-3-obesity-drug-phase-iia-bpifrance-funding20261119120125.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/innate-pharma-iph4502-phase-1-data-ena-2026-adc-linker-stability</loc>
    <lastmod>2026-11-19T11:51:01+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T00:00:00+05:30</news:publication_date>
      <news:title>Innate Pharma Reports Phase 1 Results for IPH4502 ADC</news:title>
      <news:keywords>Innate Pharma</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/innate-pharma-iph4502-phase-1-adc-linker-stability-ena-202620261119115010.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/merck-discontinues-bellwave-011-phase-3-nemtabrutinib-dmc-review</loc>
    <lastmod>2026-11-19T11:45:19+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T00:00:00+05:30</news:publication_date>
      <news:title>Merck Discontinues BELLWAVE-011 Phase 3 Trial for Nemtabrutinib</news:title>
      <news:keywords>Merck</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/merck-nemtabrutinib-bellwave-011-phase-3-discontinuation20261119114404.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/fda-launches-global-reliance-disclosure-program-nme-bla-january-2027</loc>
    <lastmod>2026-11-18T22:40:41+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T00:00:00+05:30</news:publication_date>
      <news:title>FDA Launches Global Reliance Disclosure Program, Expanding NME and BLA</news:title>
      <news:keywords>FDA</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/ddff00b4-40c4-4240-8eb5-9508141d5762/26a146c8-ae41-4860-8d15-5ca931d303eb.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/fda-draft-guidance-bayesian-methodology-clinical-trials-drug-biologics</loc>
    <lastmod>2026-11-19T11:41:43+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T00:00:00+05:30</news:publication_date>
      <news:title>FDA Draft Guidance Sets Bayesian Methods for Drug Trials</news:title>
      <news:keywords>FDA</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/fda-bayesian-methodology-draft-guidance-clinical-trials-drugs-biologics20261119113704.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/nuvalent-fda-accelerated-approval-neladalkib-alk-positive-nsclc</loc>
    <lastmod>2026-11-19T11:28:44+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T00:00:00+05:30</news:publication_date>
      <news:title>Nuvalent Gains FDA Accelerated Approval for Neladalkib in NSCLC</news:title>
      <news:keywords>Nuvalent</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/nuvalent-neladalkib-nelkarmi-fda-approval-alk-positive-nsclc20261119112824.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/mandos-fda-approval-lembaz-infantile-onset-niemann-pick-disease-type-c</loc>
    <lastmod>2026-11-19T11:22:42+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T00:00:00+05:30</news:publication_date>
      <news:title>Mandos Secures FDA Approval for Lembaz in Infantile-Onset NPC</news:title>
      <news:keywords>Mandos</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/mandos-lembaz-fda-approval-infantile-onset-niemann-pick-disease-type-c20261119112140.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/viatris-acquires-pacira-biosciences-exparel-iovera-deal-complete</loc>
    <lastmod>2026-11-19T11:13:20+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T00:00:00+05:30</news:publication_date>
      <news:title>Viatris Completes $1.65B Acquisition of Pacira BioSciences</news:title>
      <news:keywords>Viatris</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/viatris-pacira-acquisition-complete-exparel-zilretta20261119111220.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/greenwich-lifesciences-sabcs-2026-flamingo-01-abstracts</loc>
    <lastmod>2026-11-19T11:07:18+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-17T00:00:00+05:30</news:publication_date>
      <news:title>Greenwich LifeSciences Gets Two Abstracts Accepted for SABCS 2026</news:title>
      <news:keywords>Greenwich</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/greenwich-lifesciences-flamingo-01-sabcs-2026-abstracts20261119110548.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/hikma-umang-vohra-board</loc>
    <lastmod>2026-11-17T15:24:34+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-17T00:00:00+05:30</news:publication_date>
      <news:title>Hikma Pharmaceuticals Appoints Ex-Cipla CEO Umang Vohra to Board</news:title>
      <news:keywords>Hikma Pharmaceuticals, Umang Vohra, Cipla, Non-Executive Director, Board of Directors, Cohance Lifesciences, generic pharmaceuticals</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/hikma-umang-vohra-board-appointment20261117152302.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/bioxcel-therapeutics-fda-approval-at-home-agitation-treatment-schizophrenia-bipolar</loc>
    <lastmod>2026-11-18T22:37:07+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-17T00:00:00+05:30</news:publication_date>
      <news:title>Bioxcel Therapeutics Gains FDA Approval for First At-Home Agitation Treatment in Schizophrenia and Bipolar Disorder</news:title>
      <news:keywords>Bioxcel</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/b9430af6-4c73-476f-b08b-3759fc03799e/a26db997-8859-4031-bffe-9c8b3068f197.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/ideaya-biosciences-fda-type-c-ide849-registrational-strategy-neuroendocrine-carcinomas</loc>
    <lastmod>2026-11-18T12:08:42+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-17T00:00:00+05:30</news:publication_date>
      <news:title>IDEAYA Biosciences Aligns with FDA on IDE849 Trial Strategy</news:title>
      <news:keywords>IDEAYA</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/ideaya-ide849-fda-type-c-nec-registrational-trial-strategy20261118120309.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/genentech-fda-approval-giredestrant-everolimus-esr1-mutated-metastatic-breast-cancer</loc>
    <lastmod>2026-11-18T11:55:21+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-17T00:00:00+05:30</news:publication_date>
      <news:title>FDA Approves Giredestrant Plus Everolimus for Breast Cancer</news:title>
      <news:keywords>FDA</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/fda-giredestrant-wilserdly-everolimus-esr1-breast-cancer-approval20261118115412.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/cue-biopharma-phase-2-csu-durability-data-cue-401-first-in-human-dosing</loc>
    <lastmod>2026-11-18T11:45:59+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-17T00:00:00+05:30</news:publication_date>
      <news:title>Cue Biopharma Reports Phase 2 CSU Data and CUE-401 Dosing</news:title>
      <news:keywords>Cue Biopharma</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/cue-biopharma-cue-221-csu-durability-cue-401-phase-1-dosing20261118114346.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/mankind-pharma-signs-exclusive-india-deal-betta-pharmaceuticals-ensartinib-alk-nsclc</loc>
    <lastmod>2026-11-18T11:40:20+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-17T00:00:00+05:30</news:publication_date>
      <news:title>Mankind Pharma Secures Exclusive India Rights for Ensartinib</news:title>
      <news:keywords>Mankind</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/mankind-pharma-ensartinib-betta-india-licensing-deal-alk-lung-cancer20261118113652.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/lantheus-achieves-phase-3-endpoints-tauklarify-tau-pet-early-alzheimers</loc>
    <lastmod>2026-11-18T11:26:14+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-17T00:00:00+05:30</news:publication_date>
      <news:title>Lantheus Meets Phase 3 Endpoints for TAUKLARIFY PET</news:title>
      <news:keywords>Lantheus</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/lantheus-tauklarify-phase-3-early-alzheimers-tau-pet-results20261118112442.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/ucb-fda-approval-klygefa-dual-binding-nanobody-c5-inhibitor-gmg</loc>
    <lastmod>2026-11-17T11:29:01+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-17T00:00:00+05:30</news:publication_date>
      <news:title>UCB Gains FDA Approval for Klygefa as First Dual-Binding Nanobody C5 Inhibitor</news:title>
      <news:keywords>UCB</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/bf9c78ec-f5fb-44f9-8827-7c34bfabed8b/2981ecf6-4533-40b9-bcba-3c3ded747cc1.png</image:loc>
    </image:image>
  </url>
</urlset>